AUSTRALIA’S largest and most popular acid reflowing treatment, a treatment for acid refleukosis (also known as acid refractory colitis) is being developed by the Australian Medical Association (AMA).

This comes after more than 30 people, including the CEO of the AMA, have died from COVID-19-related coronavirus coronaviral complications, including COVID pneumonia.

The AMA’s President Peter Greste said the group was pleased to see the latest developments in the research and development of a treatment.

“We are excited to see that the Australian government is working towards creating a treatment that can be offered to Australians to treat COVID, a disease that affects an estimated two million Australians,” Mr Grestec said.

“This is a huge step forward for our state, our nation and the global community.”

The AMA said it had not heard from any Australian patients with COVID symptoms or concerns about the efficacy of the treatment.

However, a spokesperson for the AMA said there was no shortage of information about the disease.

“There is currently no shortage or shortage of people who are suffering from COID-19, but they have to deal with a massive burden of healthcare costs and are faced with the task of navigating their way through this world,” he said.

The new treatment is currently being developed in collaboration with Dr Paul Wills of the University of Queensland and Dr Mark Whelan of the Australian National University.

Mr Greses said he believed the treatment could be rolled out within a decade.

“It is a much more advanced version of what we are doing now and it is more robust,” he told

“What we are hoping for is to be able to start in the next two to three years, hopefully to have the treatment available to Australians in five years.”

A key advantage of the acid refluid treatment is that it can be administered at home.

Dr Whelans said the treatment had been developed using a combination of a vaccine and the combination of COVID therapy and intravenous fluids.

“The vaccine is based on the current vaccine, and the vaccine works really well,” he explained.

“But it does not work in isolation and the intravenous fluid that is given to patients is a very different approach to that used in the treatment.”

The research also revealed the potential of the drug to treat people who were not previously able to receive the treatment due to their underlying medical conditions.

The researchers believe the treatment is not only safe, but may also be more effective than traditional COVID treatment because it is targeted to the underlying disease and does not require frequent blood transfusions.

The research team said they were also looking into ways to improve the efficacy and effectiveness of the vaccine.

“There are some exciting areas of research that are being pursued that could help us reach the next stage in this research,” Dr Whemec said, adding that further work would be needed to refine the results.

The latest research also included the use of genetic testing to determine whether people with the genetic disorder were actually at risk for developing COVID.